What "treatment-resistant" really means
You are not the problem. Roughly one in three people with major depression don't respond meaningfully to standard antidepressants. Treatment-resistant depression is a medical diagnosis, and ketamine is one of the most effective tools we have for it.
Our protocol
Most TRD patients begin with an IV series — six infusions over 2–3 weeks — followed by maintenance dosing tailored to your response. We work alongside your psychiatrist or primary care provider when desired.
Why ketamine works when SSRIs don’t
SSRIs and SNRIs work on the brain’s serotonin and norepinephrine systems and typically take 4–8 weeks to take effect. Ketamine works on a completely different system — glutamate and NMDA receptors — and triggers the rapid growth of new neural connections. For many TRD patients, this is the first treatment that has ever produced a real, felt change.
Response rates we see
- Roughly 70% of TRD patients respond meaningfully to a structured series
- Many notice improvement within 1–3 sessions
- Maintenance dosing extends and stabilizes the response
- Many patients reduce (with their prescriber’s guidance) the number of other medications they need
What we’ll discuss in your consultation
We’ll review your full medication history, prior diagnoses, current providers, and treatment goals. If ketamine isn’t the right fit, we’ll say so plainly and help point you to the next best option.
Coordinated care
TRD is rarely treated in isolation. We coordinate openly with your psychiatrist, primary care provider, and therapist so that ketamine becomes one part of an integrated plan — not another silo.